课题基金 / 基金详情

SuperGAGs for Intravesicular Treatment of Interstitial Cystitis

SuperGAGs for Intravesicular Treatment of Interstitial Cystitis
用于间质性膀胱炎膀胱内治疗的 SuperGAG
批准号:
10205046
负责人:
ROBERT Evan HURST
金额:
$126.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-06-01 至 2023-06-30
关键词:
Abdominal PainAdherenceAffinityAmericanAnimal ModelBindingBiological AssayBiopolymersBladderBrainCCL2 geneChargeChelating AgentsChemicalsChemistryChondroitin SulfatesChronicChronic DiseaseClinicalClinical TrialsConsultationsCyclic GMPDataDevelopmentDevicesDiseaseEffectivenessEtiologyExtravasationFDA approvedFaceFamilyFiltrationFluorescent DyesFutureGenerationsGlycosaminoglycansGoalsHeparinHumanHydrophobicityIncreased frequency of micturitionInflammationInflammatoryInterstitial CystitisIntravesical AdministrationInvestigationIrritable Bowel SyndromeLabelLeadLectinLigandsMagnetic Resonance ImagingMeasuresMediatingMedicalMedical DeviceMethodsModalityModelingMolecular WeightMorbidity - disease rateNormal RangeOrganPainPatientsPelvic PainPerformancePermeabilityPhasePreparationProcessProteoglycanRattusResearch ContractsSafetySmall Business Innovation Research GrantSpinalStructureSurfaceSymptomsSystemTestingTherapeuticTimeTissue BanksTissuesToxicologyTransgenic MiceTreatment EfficacyUnited StatesUrge IncontinenceUrotheliumVisceral painWaterbiomaterial compatibilitychronic painclinical candidateclinical developmentclinical materialcomorbiditycompare effectivenesscontrast enhanceddesigneffective therapyhyaluronateimprovedinnovationmeetingsmicturition urgencymouse modelnovelnovel therapeuticspolysulfated glycosaminoglycanpre-clinicalpreclinical developmentpreclinical evaluationpreclinical studyprogramsresearch clinical testingresidenceresponserestorationsafety studyscale upsolutesuccesstherapeutic candidatetreatment strategyurinary

项目摘要

项目成果

ROBERT Evan HURST的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 这个第二阶段SBIR项目的目标是推进间质性膀胱炎/膀胱痛的新疗法 综合征(IC/BPS)进入临床试验。IC/BPS是一种慢性疾病,以下骨盆疼痛、尿路疼痛为特征 紧迫度和频率,并敦促大小便失禁。慢性疼痛是由于保护性 膀胱壁的糖胺聚糖(GAG)层,导致通透性和尿漏。几乎没有几个 治疗选择和批准的治疗方法取得的成功有限。因此,400万到1200万 患有IC/BPS的美国人一生都面临着慢性衰弱腹痛和其他症状。 恢复膀胱不通透性的一个有希望的治疗方案是GAG补充疗法。然而, 目前使用的单链、低分子量(MW)的GAG不能正确地模拟蛋白多糖- 与正常尿路上皮结合的GAG层,反应率低。蛋白多糖显示多个 团簇中的硫酸盐化的Gag链,形成高阴离子电荷和结合水的区域。 Glycolgix开发了一种新的、创新的高MW、支化生物聚合物家族,称为 模仿蛋白多聚糖结构的超级粘合剂。超级棒的设计是为了提高 由于其较大的尺寸、树枝状结构和对膀胱表面的亲和力而附着于尿路上皮。在……里面 第一代超微球的一期工程、合成及临床前评价成功 展示了制备大型超高生物聚合物(MW>1MDA)的概念证明,以及 这些生物聚合物恢复膀胱不通透性和减少内脏疼痛的能力 大鼠膀胱通透性模型。这一结果在第二个模型中得到证实,在该模型中,膀胱通透性 是通过炎症过程诱导的,膀胱通透性是用磁力 磁共振成像(MRI)。 在这个第二阶段的项目中,目标1是合成和表征少量的超高糖衍生物 承载靶向配体和其他已知的使用方法增强与膀胱壁的结合的基团 在第一阶段得到验证。第二个目标是比较这些生物聚合物在一只健康的小鼠身上的有效性。 炎症诱导膀胱通透性的IC/BPS模型定量对比- 增强MRI将用于测量膀胱不通透性的恢复情况。最长的恶作剧 将选择坚持时间、最紧密的结合和最有效的方法进行临床开发。目标3将 通过执行所需的GLP安全性研究和GMP,启动SuperGag临床候选药物的开发 与FDA的投入相一致的合成。在第二阶段项目结束时,Glycolgix打算 向FDA提交研究设备豁免,以获得启动人体临床试验的批准 作为IC/BPS患者的一种新的医疗器械选择。
英文摘要
PROJECT SUMMARY/ABSTRACT The goal of this Phase II SBIR project is to advance a new treatment for interstitial cystitis/bladder pain syndrome (IC/BPS) to clinical trials. IC/BPS is a chronic disease characterized by lower pelvic pain, urinary urgency and frequency, and urge incontinence. Chronic pain results from a disruption of the protective glycosaminoglycan (GAG) layer of the bladder wall, causing permeability and urinary leakage. There are few therapeutic options and approved treatments have met with limited success. Hence, the 4-12 million Americans suffering with IC/BPS face a lifetime of chronic debilitating abdominal pain and other symptoms. One promising treatment option to restore bladder impermeability is GAG replenishment therapy. However, the single chain, low molecular weight (MW) GAGs that are currently used do not properly mimic the proteoglycan- bound GAG layer of the normal urothelium, and response rates are low. Proteoglycans display multiple sulfated GAG chains in clusters, creating zones of high anionic charge and bound water. Glycologix has developed a novel and innovative family of high MW, branched biopolymers known as SuperGAGs that mimic the structure of proteoglycans. SuperGAGs have been designed to improve adherence to the urothelium due to their greater size, dendritic structure, and affinity for the bladder surface. In the Phase I project, synthesis and preclinical evaluation of first-generation SuperGAGs successfully demonstrated proof of concept for the preparation of large SuperGAG biopolymers (MW > 1MDa), and the ability of these biopolymers to restore bladder impermeability and reduce visceral pain in a well-characterized rat model of bladder permeability. This result was confirmed in a second model in which bladder permeability was induced through an inflammatory process and bladder permeability was quantified using magnetic resonance imaging (MRI). In this Phase II project, Aim 1 is to synthesize and characterize a small number of SuperGAG derivatives bearing targeting ligands and other groups known to enhance binding to the bladder wall using methods validated in Phase I. Aim 2 is to compare the effectiveness of these biopolymers in a well-established mouse model of induced IC/BPS in which bladder permeability is induced by inflammation. Quantitative contrast- enhanced MRI will be used to measure restoration of bladder impermeability. The SuperGAG with the longest adherence time, tightest binding and most effectiveness will be selected for clinical development. Aim 3 will initiate development of the SuperGAG clinical candidate by executing required GLP safety studies and GMP synthesis in concert with input from the FDA. At the conclusion of the Phase II project, Glycologix intends to submit an Investigational Device Exemption with the FDA to gain approval for initiation of human clinical trials of SuperGAG Bladder Instillate as a new medical device treatment option for patients suffering with IC/BPS.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
SuperGAG biopolymers for treatment of excessive bladder permeability.
Supergag生物聚合物治疗过度膀胱渗透性。
DOI: 10.1002/prp2.709
发表时间: 2021-03
期刊: Pharmacology research & perspectives
影响因子: 2.6
作者: [Towner RA, Greenwood-Van Meerveld B, Mohammadi E, Saunders D, Smith N, Sant GR, Shain HC, Jozefiak TH, Hurst RE]
通讯作者: Hurst RE
The Role of Altered Permeability in Bladder Diseases
The Role of Altered Permeability in Bladder Diseases
The Role of Altered Permeability in Bladder Diseases
INGENUITY SOFTWARE FOR PATHWAY AND NETWORK ANALYSIS
海外基金